Market News for Astrazeneca Plc spons Adr (AZN)
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured US approval for Baxfendy, the first in a new class of blood pressure medication to reach the market in more than two decades. The drug works by blocking production of aldosterone, a hormone that can raise blood pressure to dangerous levels and increase the risk of heart and kidney damage....
Proactive Investors - 5/18/2026 2:55:22 AM
More News for AZN
Stock Analysis for AZN
Related Stocks:
The pharmaceutical company expects the drug Baxfendy to generate multibillion-dollar annual sales at its peak....
WSJ - 5/18/2026 2:13:00 AM
More News for AZN
Stock Analysis for AZN
Related Stocks:
Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill baxdrostat had been approved in the United States, offering a new treatment option for millions of patients with uncontrolled high blood pressure despite existing medicines....
Reuters - 5/18/2026 2:01:57 AM
More News for AZN
Stock Analysis for AZN
Related Stocks:
AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart....
Zacks Investment Research - 5/15/2026 1:41:13 PM
More News for AZN
Stock Analysis for AZN
Related Stocks:
